前动力蛋白受体2在心脑血管及神经退行性疾病治疗中的研究进展  

Research progress of PK2 in treatment of cardio-cerebrovascular and neurodegenerative diseases

作　　者：李峰 付建华[1] 张路[2] 姚明江[1] LI Feng;FU Jian-hua;ZHANG Lu;YAO Ming-jiang(Institute of Basic Medical Sciences of Xiyuan Hospital,China Academy of Chinese Medical Sciences,Beijing Key Laboratory of Pharmacology of Chinese Materia Medica;Dept of Acupuncture and Moxibustion,Xiyuan Hospital of China Academy of Chinese Medical Sciences,Beijing 100091,China)

机构地区：[1]中国中医科学院西苑医院基础医学研究所,中药药理北京市重点实验室 [2]中国中医科学院西苑医院针灸科,北京100091

出　　处：《中国药理学通报》2024年第8期1401-1407,共7页Chinese Pharmacological Bulletin

基　　金：中国中医科学院科技创新工程重大攻关项目(No.C12021A01305,C12021A00912);国家中医药管理局中医药创新团队及人才支持计划项目(No.ZYYCXTD-C-202007)。

摘　　要：心脑血管及神经退行性疾病是好发于中老年人群的常见疾病,具有较高的致残率和病死率,严重威胁着人类健康。前动力蛋白受体2(prokineticin 2,PK2)是新发现的一种分泌性蛋白,通过与其受体(prokineticin receptor,PKR)1或2结合,在许多生理病理过程中发挥着重要的作用。与PK2/PKRs相关的众多研究显示,该信号通路在心脑血管及神经退行性疾病的发生发展过程中扮演着十分重要的角色,通过研究探讨它们之间的联系,PK2/PKRs将可能成为临床上治疗该类疾病的新靶点。Cardio-cerebrovascular and neurodegenerative diseases are diseases of high-incidence diseases among middle-aged and elderly people,with high disability and mortality rates,which seriously threaten human health.PK2 is a newly discovered secreted protein that plays an important role in many physiological and pathological processes by binding to its receptor PKR1 or 2.Numerous studies related to PK2/PKRs have shown that this signaling pathway also plays a very important role in the occurrence and development of cardiovascular,cerebrovascular and neurodegenerative diseases,and through exploring the connection between them,PK2/PKRs may become a new target for the clinical treatment of these diseases.

关 键 词：前动力蛋白受体 心血管疾病 脑血管疾病 神经退行性疾病 作用机制 

分 类 号：R341[医药卫生—基础医学] R392.11R540.22R743.022R745.702.2